Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Role of KLF5 in enhancing ovarian cancer stemness and PARPi resistance: mechanisms and therapeutic targeting

Fig. 4

Inhibiting KLF5 improves PARPi sensitivity in PARPi-resistant ovarian cancer. A Cell viability curve of different KLF5 knock down A2780-olaR cells and corresponding control cells exposed to different concentrations of olaparib for 72 h. B Statistical diagram of apotosis cells in different KLF5 knock down A2780-olaR cells and corresponding control cells with DMSO or olaparib. C Cell viability curve of different KLF5 knock down SKOV3-olaR cells and corresponding control cells exposed to different concentrations of olaparib for 72 h. D Statistical diagram of apotosis cells in different KLF5 knock down SKOV3-olaR cells and corresponding control cells with DMSO or olaparib. E Cell viability curve of A2780-olaR cells exposed to different concentrations of olaparib, ML264 and the combination for 72 h. F Statistical diagram of apotosis cells in A2780-olaR cells exposed to olaparib, ML264 and the combination for 72 h. G Western blot image of pro-PARP1 (the full-length PARP1 used for background quantification of Cleaved PARP1) and cleaved-PARP1, Bax, Bcl2, pro-caspase3 and cleaved-caspase3 protein expression in A2780-olaR cells exposed to olaparib, ML264 and the combination. H Cell viability curve of SKOV3-olaR cells exposed to different concentration of olaparib, ML264 and the combination for 72 h. I Statistical diagram of apotosis cells in SKOV3-olaR cells exposed to olaparib, ML264 and the combination for 72 h. J Western blot image of pro-PARP1 and cleaved-PARP1, Bax, Bcl2, pro-caspase3 and cleaved-caspase3 protein expression in SKOV3-olaR cells exposed to olaparib, ML264 and the combination. K Heatmap of combination index (CI) values for combination treatment between olaparib and ML264 in A2780-olaR. L CI values for the entire fraction affected (Fa) of A2780-olaR. M Heatmap of combination index (CI) values for combination treatment between olaparib and ML264 in SKOV3-olaR. N CI values for the entire fraction affected (Fa) of SKOV3-olaR. P value was obtained by ANOVA analysis. Results represent the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page